Therapy of spinal muscular atrophy using suberoylanilide hydroxamic acid, a second generation histone deacetylase inhibitor

被引：0
|
作者：
Hahnen, E [1 ]
Eyüpoglu, IY [1 ]
Brichta, L [1 ]
Haastert, K [1 ]
Tränkle, C [1 ]
Siebzehnrübl, FA [1 ]
Riessland, M [1 ]
Hölker, I [1 ]
Claus, P [1 ]
Romstöck, J [1 ]
Buslei, R [1 ]
Wirth, B [1 ]
Blüumcke, I [1 ]
机构：
[1] Univ Cologne, Inst Humangenet, D-50931 Cologne, Germany
来源：
ACTA NEUROPATHOLOGICA | 2005年 / 110卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：326 / 326
页数：1
相关论文
共 50 条
  • [31] Histone deacetylase inhibitor suberoylanilide hydroxamic acid targets breast cancer stem cells and inhibits metastasis
    Chu, K.
    Green, T. L.
    Boley, K. M.
    Cristofanilli, M.
    Robertson, F. M.
    CANCER RESEARCH, 2013, 73
  • [32] Suppressive Effect of the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) on Hepatitis C Virus Replication
    Sato, Ayami
    Saito, Yoshimasa
    Sugiyama, Kazuo
    Sakasegawa, Noriko
    Muramatsu, Toshihide
    Fukuda, Shinya
    Yoneya, Mikiko
    Kimura, Masaki
    Ebinuma, Hirotoshi
    Hibi, Toshifumi
    Ikeda, Masanori
    Kato, Nobuyuki
    Saito, Hidetsugu
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (09) : 1987 - 1996
  • [33] A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Kelly, W
    O'Connor, O
    Richon, VM
    Tong, W
    Rao, TD
    Chiao, J
    O'Brien, JP
    Rifkid, RA
    Marks, PA
    Scher, HI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S88 - S88
  • [34] In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy
    Hahnen, E
    Eyüpoglu, IY
    Brichta, L
    Haastert, K
    Tränkle, C
    Siebzehnrübl, FA
    Riessland, M
    Hölker, I
    Claus, P
    Romstöck, J
    Buslei, R
    Wirth, B
    Blümcke, I
    JOURNAL OF NEUROCHEMISTRY, 2006, 98 (01) : 193 - 202
  • [35] Histone deacetylase inhibitors against spinal muscular atrophy
    Hahnen, E
    Eyüpoglu, IY
    Siebzehnrübl, F
    Buslei, R
    Jungbauer, T
    Brichta, L
    Wirth, B
    Blümcke, I
    ACTA NEUROPATHOLOGICA, 2004, 108 (04) : 362 - 363
  • [36] Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A
    Codd, Rachel
    Braich, Najwa
    Liu, Joe
    Soe, Cho Zin
    Pakchung, Amalie A. H.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (04): : 736 - 739
  • [37] Histone deacetylase inhibitors: Development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers
    Richon, VM
    Zhou, XB
    Rifkind, RA
    Marks, PA
    BLOOD CELLS MOLECULES AND DISEASES, 2001, 27 (01) : 260 - 264
  • [38] The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice
    Sangeetha Sukumari-Ramesh
    Cargill H. Alleyne
    Krishnan M. Dhandapani
    Translational Stroke Research, 2016, 7 : 141 - 148
  • [39] Anti-angiogenic effect of vorinostat (suberoylanilide hydroxamic acid, SAHA), a histone deacetylase inhibitor, in CTCL lesions
    Ni, X.
    Kelly, C.
    Talpur, R.
    Zhang, C.
    Breuer-McHam, J.
    Richon, Vm
    Duvic, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 2 - 2
  • [40] Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of α1-Antitrypsin Deficiency
    Bouchecareilh, Marion
    Hutt, Darren M.
    Szajner, Patricia
    Flotte, Terence R.
    Balch, William E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (45)
12345